# OnCo record nct05508906 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05508906/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05508906", "NCT05508906" ;
  schema:name "Palazestrant combination study"@en ;
  schema:alternateName "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer"@en ;
  schema:description "This early study tests palazestrant with ribociclib, alpelisib, everolimus or atirmociclib. It seeks suitable combination doses and evaluates side effects and drug levels."@en ;
  schema:url <https://onco.cc/trials/nct05508906/> ;
  schema:dateModified "2026-10-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05508906>, <https://clinicaltrials.ucsf.edu/trial/NCT05508906> ;
  onco:status "active" ;
  onco:tag "ucsf-breast-coverage", "interventional" ;
  onco:phase "1" ;
  schema:startDate "2022-08-31" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:drugs <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/drugs/atirmociclib/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/ribociclib/> ;
  onco:institutions <https://onco.cc/institutions/ucsf/> .